News

As part of the transaction, the company will transfer 13 of its portfolio company holdings to a new private holding company, KDev Investments, which will include portfolio of

Fast Track facilitates the development and expedites the review of new drugs intended to serve unmet medical needs in serious or life-threatening conditions. Lexicon Pharmaceuticals senior vice president

As part of the agreement, Cosmo Pharmaceuticals, using its proprietary MMX technology will formulate new human monoclonal antibodies generated by AIMM Therapeutics in an extended release form. AIMM

ImmunoGen president and CEO Daniel Junius said major healthcare companies are interested in developing multiple product candidates with TAP technology. "In recent years, there has been a marked

Established in 1987, HCR is headquartered in Munich, Germany and operates across Europe, Israel and South America in addition to a US office in Princeton, New Jersey. With

The submission was based on a comprehensive clinical development program, in which BEMFOLA had shown to be statistically equivalent to the reference product in patients participating in an

Omni Bio is involved in developing alternative uses of Alpha-1 antitrypsin (AAT), designed for treating various indications, as well as recombinant forms of AAT. Prior to joining the

Solithromycin, the company’s fluoroketolide antibiotic candidate, is designed for treating patients with community-acquired bacterial pneumonia (CABP). The study, which will enroll approximately 800 patients with PORT-II to PORT-IV

HPA seasonal flu surveillance head Richard Pebody said HPA is seeing an increase in flu activity mainly among school children indicating the start of this year’s flu season.